{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Grade(G)4 neutropenia \\>5 day; febrile neutropenia (absolute neutrophil count \\[ANC\\] \\<1000/millimeter cube (mm\\^3) with single temperature \\>38.3 degree Celsius (deg C) or sustained temp\\>=38 deg C for \\>1 hour(H); G\\>=3 neutropenia with infection; G4 thrombocytopenia (unless baseline count \\>=25,000/mm\\^3 and \\<50,000/mm\\^3, in which case G4 thrombocytopenia to be accompanied by \\>=G2 bleeding); Platelet count \\<10,000/mm\\^3; G3 thrombocytopenia with \\>=G2 bleeding; G\\>=4 AE; G3 cytokine release syndrome(CRS) except CRS not maximally treated/improved to \\<=G1 within 48H; G3 AE except AE attributed to CRS, G3 nausea,vomiting,diarrhea improved to G\\<=2 within 72H after medical management, G3 fatigue \\<1 week, G3 AE recovered to baseline/G1 within 5 day; confirmed drug-induced liver injury; G3-4 laboratory (lab) abnormality except G3-4 lab abnormality improved to G\\<=2 within 72H after medical management \\& without sequelae;G3 injection site reaction; G2/other clinically important AE may be considered DLT.","groups":[{"description":"Participants received SC elranatamab with a priming regimen of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW thereafter starting from Cycle 1 Day 8.","id":"OG000","title":"Phase 1b"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT evaluable analysis set included all participants enrolled to Phase 1b part and who had a DLT in the DLT observation period or completed the DLT observation period without DLT. Participants without DLTs and without the minimum required exposure for reasons other than treatment-related toxicity were not evaluable for DLTs and were replaced.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (28 days)","title":"Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)","type":"PRIMARY","unitOfMeasure":"Participants"}